PDK4 functions as a tumor suppressor in GC, bridging metabolic reprogramming, epigenetic regulation, and immune microenvironment remodeling. Its downregulation contributes to disease progression and immune evasion, underscoring its potential as a prognostic biomarker and therapeutic target. Restoring PDK4 activity may serve as a promising strategy to mitigate GC aggressiveness and therapeutic resistance.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: